Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer
作者:Hao Cui、Zan Hu、Kang Yang、Jingkun Huang、Yichao Wu、Quanwei Chen、Ran Wei、Penfeng Wang、Hui Wang、Hongmei Li、Yadong Chen、Tao Lu、Yuqin Yao、Yong Zhu
DOI:10.1016/j.ejmech.2022.114484
日期:2022.8
pathway can promote cancer cell apoptosis. Histone deacetylases (HDACs) also are promising drug targets for cancers, and their synergistic effect with TRAIL can improve the inhibitory effect on cancer cells. Therefore, the development of highly TRAIL-sensitive HDAC inhibitors might be a promising strategy for the treatment of cancers. We synthesized a series of HDAC inhibitors by introducing effective
激活 TRAIL 促凋亡通路可促进癌细胞凋亡。组蛋白去乙酰化酶(HDACs)也是很有前景的癌症药物靶点,其与TRAIL的协同作用可以提高对癌细胞的抑制作用。因此,开发对 TRAIL 高度敏感的 HDAC 抑制剂可能是治疗癌症的有希望的策略。我们通过引入对TRAIL敏感的有效片段合成了一系列HDAC抑制剂。与ONC201相比,化合物IIc对HDAC1和HCT116细胞具有良好的抑制活性,对激活TRAIL蛋白表达和促进HCT-116细胞凋亡的敏感性更高。化合物IIc的抑制活性在 HCT-116 异种移植模型中 (25 mg/kg) 显着高于阳性对照药物 (ONC201, chidamide)。这些发现表明高度敏感的HDAC抑制剂可作为结直肠肿瘤药物的开发。